Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT-MRD: ctDNA-guided adjuvant therapy in pancreatic cancer
NCT06966440Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of adjuvant chemotherapy in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Disease Free Survival at 3 years. Started Jun 2025; status: recruiting.
02
Drugs
adjuvant chemotherapy
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06966440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06966440.